Source comparison
Melanotan-1 vs PT-141: Clinical Applications Comparison
Melanotan-1 and PT-141 serve entirely non-overlapping clinical indications—there is no scenario where they are therapeutically interchangeable. Below is a structured comparison of approved indications, off-label research applications, and regulatory status for
This comparison does not assign a generated winner or score.
- Melanotan-1 and PT-141 serve entirely non-overlapping clinical indications—there is no scenario where they are therapeutically interchangeable. Below is a structured comparison of approved indications, off-label research applications, and regulatory status for each peptide.
- Primary Mechanism
- MC1R agonist → melanogenesis in dermal melanocytes → photoprotection via eumelanin deposition
- MC4R agonist → hypothalamic modulation → dopamine/oxytocin release → sexual arousal
- FDA Approval Status
- Approved 2019 (Scenesse) for erythropoietic protoporphyria (EPP) to increase pain-free sun exposure
- Approved 2019 (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women
- Standard Dosing
- 0.25mg SC daily × 7–10 days (loading), then 0.25mg 2–3×/week (maintenance)
- 1.75mg SC 45 min before sexual activity, max once per 24 hours
- Onset of Effect
- Visible tanning: 5–7 days; peak photoprotection: 10–14 days
- Sexual arousal: 45–90 minutes; peak effect: 2–3 hours
- Half-Life / Duration
- Plasma t½: 33 min; biological effect (melanin): weeks to months
- Plasma t½: 2.7 hours; clinical effect: 6–8 hours
- Most Common Adverse Events
- Nausea (15–20%), facial flushing (10–15%), hyperpigmentation of nevi (expected)
- Nausea (40–50%), flushing (15–25%), transient hypertension (10%), headache (10–15%)
- Research Applications
- Vitiligo repigmentation, photodermatosis prophylaxis, cosmetic tanning (non-FDA)
- Erectile dysfunction (male), anorgasmia, SSRI-induced sexual dysfunction
- Contraindications
- Melanoma history, dysplastic nevus syndrome, photosensitivity disorders
- Uncontrolled hypertension, cardiovascular disease, pregnancy/breastfeeding
- Bottom Line
- Gold standard for photoprotection in photosensitivity diseases; cosmetic tanning requires chronic dosing with UV co-exposure. No meaningful sexual effects at standard doses.
- Most effective melanocortin-based treatment for female hypoactive desire; high nausea rate limits tolerability. Zero tanning or photoprotection.
- The table clarifies the fundamental divide: Melanotan-1 addresses dermatological pathology where photoprotection is the therapeutic goal, while PT-141 addresses psychosexual disorders where arousal pathways require pharmacological activation. Researchers interested in melanocortin biology beyond these approved indications often explore related peptides with different receptor profiles—Melanotan 2 MT2 10mg exhibits broader melanocortin receptor activity including MC1R, MC3R, and MC4R, producing both tanning and sexual effects, though it lacks FDA approval for any indication. Understanding the receptor pharmacology of melanotan-1 vs PT-141 provides the conceptual framework for evaluating other synthetic melanocortin analogs.